ZOM - Zomedica Pharmaceuticals Corp.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3000
+0.0030 (+1.01%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2970
Open0.2930
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range0.2930 - 0.3024
52 Week Range0.2000 - 1.2500
Volume44,677
Avg. Volume97,858
Market Cap33.212M
Beta (5Y Monthly)0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.2460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.65
  • GlobeNewswire

    Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced it has successfully completed the development and manufacturing milestones for its reference lab cancer liquid biopsy platform. Zomedica is developing assays for the detection of hemangiosarcoma, osteosarcoma, and lymphoma, for use with its liquid biopsy platform. Lymphoma, osteosarcoma and hemangiosarcoma are three of the top five most commonly diagnosed canine cancers.

  • Hedge Funds Have Never Been This Bullish On Zomedica Pharmaceuticals Corp. (ZOM)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Zomedica Pharmaceuticals Corp. (ZOM)

    Is Zomedica Pharmaceuticals Corp. (NYSE:ZOM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • GlobeNewswire

    Zomedica Announces Management Changes

    Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced that Gerald Solensky, Jr. has resigned as Chief Executive Officer, Chairman and a Director of Zomedica, effective immediately. Mr. Solensky will continue as a consultant to the Zomedica’s operating subsidiary, Zomedica Phamaceuticals, Inc. Shameze Rampertab, Chief Financial Officer, will act as interim CEO until a replacement is found.

  • GlobeNewswire

    Zomedica Expands ZM-006 Pilot Efficacy Study

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced today that it has widen its pilot efficacy study of ZM-006, initiated in partnership with University of Georgia’s (UGA) veterinary teaching hospital, to include Quakertown Veterinary Clinic, an American Animal Hospital Association (AAHA) accredited, high-traffic referral clinic in Pennsylvania with 37 veterinarians, of which 24 specialize in small animal health.

  • GlobeNewswire

    Zomedica Announces Third Quarter 2019 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the third quarter ended September 30, 2019.

  • GlobeNewswire

    Zomedica Announces 2019 Annual Meeting Results

    ANN ARBOR, Mich., Nov. 05, 2019 -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and health care solutions company, is.

  • GlobeNewswire

    Zomedica Commences Final TRUFORMA™ Diagnostic Verification Study

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced today that it has commenced the final verification study of the first five assays designed for use with its point-of-care diagnostic biosensor platform, TRUFORMA™. The verification study is evaluating the utility of the first five thyroid and adrenal assays intended for use with the TRUFORMA™ platform. The initial three thyroid assays are: canine and feline total T4 (thyroxine), canine free T4, and canine and feline TSH (thyroid stimulating hormone).

  • Newsfile

    CORRECTION FROM SOURCE: Zomedica Pushes TRUFORMA(TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSXV: ZOM) - In the article headline published on October 1, 2019, the reference to Zomedica's TRUFORMA companion pet diagnostic device was incorrectly titled as TRUFORM. This error was made by a third-party responsible for syndication processes and should not reflect on Zomedica, its trademarks, or its pipeline properties. A copy of the entire release follows.Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Zomedica Pharmaceuticals Corp. ...

  • Newsfile

    Zomedica Pushes TRUFORMA (TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market

    Miami Beach, Florida--(Newsfile Corp. - October 1, 2019) - Zomedica, Inc. (NYSE American: ZOM) (TSXV: ZOM) is getting closer to commercializing its first potentially industry-changing product, TRUFORMA™, a point of care diagnostic platform with initial assays used to diagnose thyroid and adrenal disorders in dogs and cats. The device, which is on pace to launch by the end of first quarter of 2020, is expecting to earn a large share of the ...

  • GlobeNewswire

    Zomedica names Dr. Stephanie Morley President

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that Dr. Stephanie Morley, Chief Operations Officer and VP of Product Development, has been promoted to the role of President of Zomedica. Dr. Morley, who joined the initial management team of Zomedica shortly after its founding, has over 15 years of experience as a life science executive and practicing veterinarian with a broad career in operations, business development and clinical veterinary practice.

  • PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.
    Newsfile

    PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.

    Developer of Diagnostic and Pharmaceutical Solutions for the Companion Animal Market with Commercialization Activities Approaching New York, New York--(Newsfile Corp. - September 11, 2019) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City and focused on small and micro-cap public companies, today announced it has initiated coverage on Zomedica Pharmaceuticals, Corp. (NYSE: ZOM) PCG Research, the equity research division of ...

  • ACCESSWIRE

    Zomedica to Present at the Fall Investor Summit on Monday, September 16 in New York City

    NEW YORK, NY / ACCESSWIRE / September 11, 2019 / Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced its Chief Financial ...

  • GlobeNewswire

    Zomedica to Present at RHK Capital 2019 Disruptive Growth Conference, Fall Investor Summit, and Sidoti & Company Fall 2019 Investor Conference

    ANN ARBOR, Mich., Sept. 03, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that.

  • GlobeNewswire

    Animal Health Veteran Johnny D. Powers Joins Zomedica Board of Directors

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced that, subject to the approval of the TSX Venture Exchange, Johnny D. Powers has been appointed to Zomedica’s board of directors as an independent director. Additionally, Powers will also serve as a member of the audit, compensation, and corporate governance committees of the board of directors. Powers has more than 30 years of experience leading business strategy, operations, sales and marketing, and product development in the human and pet medical diagnostics markets.

  • ACCESSWIRE

    Zomedica Inc. Prepares to Launch Veterinarian Diagnostic Device, TRUFORMA(TM); Has Potential to Change Diagnostic Landscape in Animal Health (NYSE American: ZOM)

    TRUFORMA™ is the company's innovative diagnostic tool that aims to replace old-fashioned methods of diagnosis that require patient samples to be sent to an outside lab for testing before therapeutic or prescription treatments can be offered. Now, with modern innovations coming to market by companies like Zomedica, a fast, accurate point-of-care diagnosis can be provided right at the clinic. In doing so, Zomedica can help to streamline the vet care industry.

  • GlobeNewswire

    Zomedica Announces Second Quarter 2019 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the second quarter ended June 30, 2019. “We have made significant progress in the first half of 2019 with our development of TRUFORMA™, Zomedica’s point-of-care biosensor platform, as well as our digital data platform and other product lines,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. $5,000,000 of the purchase price was paid in May 2019 and $7,000,000 was paid in June 2019.  The preferred shares do not have voting rights except to the extent required by applicable law and are not convertible into the Company’s common shares.

  • GlobeNewswire

    Zomedica Announces TRUFORMA™ Assay Updates and R&D Expansion

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced additional development progress on two assays for its TRUFORMA™ point-of-care biosensor platform. Development of what Zomedica believes is the first-ever point-of-care assay for canine endogenous adrenocorticotropic hormone (eACTH) and an assay for feline thyroid stimulating hormone (feline TSH) demonstrates the potential of TRUFORMA™.

  • GlobeNewswire

    Zomedica’s Dr. Bonnie Bragdon to Speak at AVMA Convention 2019 on Sunday, August 4

    ANN ARBOR, Mich., July 25, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced Dr..

  • GlobeNewswire

    Zomedica Announces Initiation of a Digital Data Platform Enhancing its Diagnostic Pipeline

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced it has initiated the development of a digital customer data platform to enhance customer experience and its diagnostic pipeline. Development efforts are focused on providing veterinarians access to diagnostic test result data and insights into patterns of disease across animal populations.

  • Zacks Small Cap Research

    ZOM: One Instrument; Multiple Solutions

    The high level of ownership stimulates the $19 billion2 in estimated veterinary care spending and the mid-single digit growth rate that the industry is experiencing. As pets become a more important part of the family, the quality of their health care is also receiving more attention. There is a parallel between improvements in therapies and diagnostics for human and animal health.

  • GlobeNewswire

    Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that it has completed initial development work on a blood-borne lymphoma cancer assay intended for use with its canine cancer liquid biopsy platform. According to the American Veterinary Medical Association, one in four dogs will develop cancer during their lifetime. Lymphomas represent approximately 10-25% of all cancers diagnosed in dogs.

  • GlobeNewswire

    Zomedica to Present at Raymond James Life Sciences and MedTech Conference

    ANN ARBOR, Mich., June 12, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

  • GlobeNewswire

    Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares

    ANN ARBOR, Mich., June 10, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical.

  • GlobeNewswire

    Zomedica Announces Achievement of Product Development Milestones on its TRUFORMA™ Point-of-Care Diagnostic Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that TRUFORMA™, its point-of-care biosensor platform, recently achieved two important product development milestones. The milestones achieved are beta finalization of the instrument design and the completion of feasibility testing of the TRUFORMA™ platform’s first assays. The standard of care for total T4, fT4, TSH, and cortisol is reference lab immunoassays generally run on expensive laboratory equipment.

  • GlobeNewswire

    Zomedica Announces First Quarter 2019 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the first quarter ended March 31, 2019. “During the quarter, we continued to advance the development of our unique product pipeline of novel diagnostics and innovative therapeutics,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. In January 2019, Zomedica announced the achievement of the product development milestone for ZM-017, our canine cancer liquid biopsy diagnostic platform, by Celsee, Inc. Celsee elected to receive its milestone payment in equity resulting in the issuance to Celsee of an aggregate of 657,894 common shares at an ascribed price of $1.52 (C$2.00).